Alzheimer’s
disease (AD) is the most prevalent neurodegenerative
disorder underlying dementia in the geriatric population. AD manifests
by two pathological hallmarks: extracellular amyloid-β (Aβ)
peptide-containing senile plaques and intraneuronal neurofibrillary
tangles comprised of aggregated hyperphosphorylated tau protein (p-tau).
However, more than half of AD cases also display the presence of aggregated
α-synuclein (α-syn)-containing Lewy bodies. Conversely,
Lewy bodies disorders have been reported to have concomitant Aβ
plaques and neurofibrillary tangles. Our drug discovery program focuses
on the synthesis of multitarget-directed ligands to abrogate aberrant
α-syn, tau (2N4R), and p-tau (1N4R) aggregation and to slow
the progression of AD and related dementias. To this end, we synthesized
11 compounds with a triazine-linker and evaluated their effectiveness
in reducing α-syn, tau isoform 2N4R, and p-tau isoform 1N4R
aggregation. We utilized biophysical methods such as thioflavin T
(ThT) fluorescence assays, transmission electron microscopy (TEM),
photoinduced cross-linking of unmodified proteins (PICUP), and M17D
intracellular inclusion cell-based assays to evaluate the antiaggregation
properties and cellular protection of our best compounds. We also
performed disaggregation assays with isolated Aβ-plaques from
human AD brains. Our results demonstrated that compound 10 was effective in reducing both oligomerization and fibril formation
of α-syn and tau isoform 2N4R in a dose-dependent manner via
ThT and PICUP assays. Compound 10 was also effective
at reducing the formation of recombinant α-syn, tau 2N4R, and
p-tau 1N4R fibrils by TEM. Compound 10 reduced the development
of α-syn inclusions in M17D neuroblastoma cells and stopped
the seeding of tau P301S using biosensor cells. Disaggregation experiments
showed smaller Aβ-plaques and less paired helical filaments
with compound 10. Compound 10 may provide
molecular scaffolds for further optimization and preclinical studies
for neurodegenerative proteinopathies.